Table 6.

Overview of included studies – base case (sensitivity analyses) presented

	Kulasingam 2003 [27]	Sanders 2003 [28]	Goldie 2004 [29]	Taira 2004 [32]	Kulasingam 2007 [39]
Country	US	US	US	US	Australia
Modelling approach	Markov Model	Markov Model	Markov Model	Deterministic transmission Model	Markov Model
Disease included	HPV, CIN1,2–3, CC	HPV,SIL, CC	HPV, CIN1,2–3, CC	HPV	HPV, CIN1,2–3, CC
HPV types (High Risk/ Low Risk)	yes/yes	16,18,31,33,35,39,45,51,52,56,58,59,68/20,22	16,18,non 16–18/yes	16,18/-	16,18,non 16–18/yes
Target population	12 F to 85 F	12 F	13 F to ≈ 17 F	12 F to 50 F	12 F to 85 F
Time horizon	12 to 85	12 to Lifetime	12 to Lifetime	12 to Lifetime	12 to 85
Discount rates	3%	3% (0–5%)	3%	2% (0–5%)	5% (3–5%)
Perspective	Societal	Societal	Societal	Societal	Societal
	Goldhaber-Fiebert 2008 [33]	Kim 2008 [31]	Coupe, de Melker 2009 [35]	Coupe, van Ginkel 2009 [36]	Kim 2009 [30]
Country	US	US	Netherlands	Netherlands	US
Modelling approach	Individual-based model	Dynamic Model	Markov Model	Markov Model	Hybrid model (transmission model + disease model)
Disease included	HPV, CIN1,2–3, CC	CIN, CC, other HPV-related disease	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC	CIN, CC, other HPV-related diseases
HPV type (High Risk/Low Risk)	16,18,non 16–18/yes	16,18/-	16,18,31,33,35,39,45,51,52,56,58,59,68/-	16,18,31,33,35,39,45,51,52,56, 58,59,66,68/-	16,18/-
Target population	9 F to Lifetime	12 F	12 F	12 F	12 F + M
Time horizon	9 to Lifetime	12 to Lifetime	12 to Lifetime	12 to Lifetime	12 to Lifetime
Discount rates	3%	3%	4% (Costs) 1.5% (Health)	4% (Costs) 1.5% (Health)	3%
Perspective	Societal	Societal	Societal	Societal	Societal
	Kim, Ortendahl 2009 [34]	Accetta 2010 [38]	Diaz 2010 [43]	Demarteau 2011 [41]	Burger 2012 [42]
Country	US	Italy	Spain	France	Norway
Modelling approach	Individual-based Model	Markov Model	Micro-simulation model	Markov Model	Simulation model
Disease included	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC
HPV type (High Risk/Low Risk)	16,18/-	16,18,non 16–18/yes	16,18,non 16–18/yes	-	16,18,non 16–18/yes
Target population	35–45 F	F	11–14 F	12 F	F
Time horizon	35–45 to Lifetime	11 to Lifetime	11 to lifetime	12 to lifetime	Lifetime
Discount rates	3%	3%	3%	3% (Costs) 1.5% (Health) (0–5%)	4%
Perspective	Societal	Societal	Societal	Societal	Societal
	Coupe 2012 [37]	Tully 2012 [40]	Berkhof 2013 [44]
Country	Netherlands	Canada	Slovenia, Poland
Modelling approach	Individual-based model	Transmission model	Individual-based model
Disease included	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC	HPV, CIN1,2–3, CC
HPV type (High Risk/Low Risk)	16,18,31,33,35,39,45,51,52,56, 58,59,66,68/-	16,18,non 16–18/-	16,18,−/−
Target population	10 F	18 F	12 F
Time horizon	10 to Lifetime	80 years	Not clear
Discount rates	4% (Costs) 1.5% (Health) (No-3%)	3%	3%
Perspective*	Societal	Societal	Societal

*Societal perspective – costs and QALYs are calculated based on health forgone as a result of costs falling on the healthcare budget and displacing other healthcare activities